For a special limited time:

         Save 30%!

 Get all 3:


  for one low price.

                Learn more

Cancer Stem Cells - Max Wicha

publication date: Feb 9, 2013
Max Wicha a cancer stem cell pioneer discusses cancer stem cells.

Note that this is quite relevant to our discussion on the ability of Incyte's JAK inhibitors to
down regulate interleukin 6 (IL-6) to impact breast cancer stem cells.  There is already a
clinical trial to investigate ruxolitinib in breast cancer as we discussed recently.

He mentions this IL-6 issue at around 8:50. 

Dr. Wicha is a founder of OncoMed pharmaceuticals a privately held company that has
a development alliance agreement with Bayer for WNT pathway drugs.